Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 34Neoplasm Metastasis 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Adenocarcinoma 2Urologic Diseases 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Radiation Injuries 1Prostatic Diseases 1Prostate Cancer Metastatic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligometastatic Prostate Cancer 1Neoplasm Recurrence, Local 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1Gastrointestinal Diseases 1Erectile Dysfunction 1Breast Neoplasms 1

Interventions

olaparib 1gallium 68 PSMA-11 1Pluvicto 1Gemcitabine 1Cisplatin 1Androgen Antagonists 1Adrenal Cortex Hormones 1Abiraterone Acetate 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Male × Androgen Antagonists × 90 days × Clear all
NCT05067140 2026-05-05

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Novartis

Phase 1/2 Active not recruiting
152 enrolled
Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡